Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Islamabad: Iran allows 20 Pakistani ships through Strait of Hormuz - 22024's Savvy Home Gadgets for an Associated Way of life
- 3Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- 4Whale stranded off Germany for days found stuck again
- 5Instructions to Keep an Inspirational perspective After Cellular breakdown in the lungs Treatment
- 'Euphoria' Season 3 trailer includes Eric Dane's final appearance, Jacob Elordi and Sydney Sweeney at the altar and Zendaya's 'Breaking Bad' era
- Jubilant FoodWorks to scrap Dunkin’ franchise arrangement in India
- Apollo vs. Artemis: What to know about NASA's return to the moon
- Israeli forces kill one person in series of attacks on southern Lebanon
- Federal judge upholds Hawaii's new climate change tax on cruise passengers
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- Misjudged Objections For Solo Voyagers
- Instructions to Redo Your Kona SUV for Improved Tasteful Allure and Usefulness
- UAE recalls some Nestle infant formula products, Qatar warns consumers
